Tirdzniecība BioMarin Pharmaceutical Inc - BMRN CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.88 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.030779% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.013666% | ||||||||
| Nakts laika nodeva | 22:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Biomarin Pharmaceutical Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 112.62 |
| Atvērt* | 112.65 |
| Izmaiņas par 1 gadu* | 27.63% |
| Dienas Diapazons* | 111.69 - 113.28 |
| 52 ned Diapazons | 70.73-117.77 |
| Vidējais apjoms (10 dienas) | 1.46M |
| Vidējais apjoms (3 mēneši) | 31.05M |
| Tirgus Kapitalizācija | 20.85B |
| Cenas/Peļņas Attiecība | 284.19 |
| Izvietotās Akcijas | 185.85M |
| Ieņēmumi | 2.01B |
| EPS | 0.39 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 0.36 |
| Nākamās Peļņas Datums | Feb 21, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Feb 3, 2023 | 111.72 | -0.63 | -0.56% | 112.35 | 113.68 | 111.21 |
| Feb 2, 2023 | 112.62 | -3.05 | -2.64% | 115.67 | 116.34 | 111.50 |
| Feb 1, 2023 | 116.50 | 2.14 | 1.87% | 114.36 | 116.68 | 113.19 |
| Jan 31, 2023 | 115.12 | 1.18 | 1.04% | 113.94 | 115.38 | 113.94 |
| Jan 30, 2023 | 114.47 | -1.80 | -1.55% | 116.27 | 116.93 | 114.14 |
| Jan 27, 2023 | 116.79 | 1.47 | 1.27% | 115.32 | 117.56 | 115.32 |
| Jan 26, 2023 | 116.58 | 1.07 | 0.93% | 115.51 | 116.94 | 114.46 |
| Jan 25, 2023 | 115.45 | 1.60 | 1.41% | 113.85 | 116.29 | 113.84 |
| Jan 24, 2023 | 113.39 | 3.30 | 3.00% | 110.09 | 113.79 | 110.09 |
| Jan 23, 2023 | 110.98 | 1.71 | 1.56% | 109.27 | 111.38 | 108.74 |
| Jan 20, 2023 | 110.47 | 1.35 | 1.24% | 109.12 | 110.86 | 108.49 |
| Jan 19, 2023 | 108.78 | -1.10 | -1.00% | 109.88 | 109.96 | 108.60 |
| Jan 18, 2023 | 110.28 | -0.81 | -0.73% | 111.09 | 111.73 | 110.15 |
| Jan 17, 2023 | 111.36 | 0.36 | 0.32% | 111.00 | 112.79 | 109.88 |
| Jan 13, 2023 | 112.27 | 1.12 | 1.01% | 111.15 | 114.58 | 110.75 |
| Jan 12, 2023 | 112.91 | 2.89 | 2.63% | 110.02 | 113.43 | 108.97 |
| Jan 11, 2023 | 110.68 | -0.47 | -0.42% | 111.15 | 112.46 | 108.79 |
| Jan 10, 2023 | 110.79 | 3.99 | 3.74% | 106.80 | 111.79 | 106.11 |
| Jan 9, 2023 | 106.58 | -2.13 | -1.96% | 108.71 | 109.86 | 105.28 |
| Jan 6, 2023 | 108.31 | 2.12 | 2.00% | 106.19 | 109.07 | 106.19 |
BioMarin Pharmaceutical Inc Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Kopējie ienākumi | 1116.85 | 1313.65 | 1491.21 | 1704.05 | 1860.45 | 1846.28 |
| Ienākumi | 1116.85 | 1313.65 | 1491.21 | 1704.05 | 1860.45 | 1846.28 |
| Cost of Revenue, Total | 209.62 | 241.786 | 315.264 | 359.466 | 524.272 | 470.515 |
| Bruto Peļņa | 907.234 | 1071.86 | 1175.95 | 1344.58 | 1336.18 | 1375.76 |
| Kopējie Darbības Izdevumi | 1920.28 | 1328.35 | 1614.74 | 1804.51 | 1897.22 | 1928.62 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 472.976 | 565.167 | 610.014 | 675.665 | 737.784 | 760.923 |
| Pētniecība un Attīstība | 661.905 | 610.753 | 696.328 | 715.007 | 628.116 | 628.793 |
| Depreciation / Amortization | 30.2 | 36.2 | 30.3 | 53.5 | 62.2 | 61.9 |
| Procentu Izdevumi (Ienākumi) - Neto Darbība | 3.617 | -10.831 | -5.661 | 5.259 | -0.115 | -1.548 |
| Neparedzēti Izdevumi (Ienākumi) | 599.118 | -125 | -50 | -25 | -59.495 | 0 |
| Other Operating Expenses, Total | -57.153 | 10.271 | 18.491 | 20.608 | 4.458 | 8.033 |
| Darbības Izdevumi | -803.429 | -14.7 | -123.524 | -100.457 | -36.765 | -82.341 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -32.55 | -29.145 | -21.386 | -1.299 | -12.705 | -4.855 |
| Citi, Neto | 4.929 | 7.97 | 2.205 | 6.945 | 7.148 | 11.846 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -831.05 | -35.875 | -142.705 | -94.811 | -42.322 | -75.35 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
| Neto Ienākumi | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
| Atšķaidītie Neto Ienākumi | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
| Atšķaidītie Ienākumi par Akcijām | 165.985 | 174.427 | 177.061 | 179.039 | 191.678 | 182.852 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -3.79679 | -0.4285 | -0.43607 | -0.1332 | 0.0238 | -0.37189 |
| Atšķaidītā Normalizētā Peļņa par Akciju | -1.45063 | -0.89431 | -0.61962 | -0.22396 | -0.17796 | -0.37189 |
| Ārkārtas Posteņi Kopā | -42.3 | 0 | 854.539 | 3.92 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 486.03 | 501.693 | 408.742 | 449.81 | 519.359 |
| Ienākumi | 486.03 | 501.693 | 408.742 | 449.81 | 519.359 |
| Cost of Revenue, Total | 120.166 | 127.062 | 103.537 | 119.75 | 116.965 |
| Bruto Peļņa | 365.864 | 374.631 | 305.205 | 330.06 | 402.394 |
| Kopējie Darbības Izdevumi | 460.944 | 490.021 | 461.961 | 515.69 | 382.032 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 174.318 | 184.161 | 183.333 | 217.563 | 194.619 |
| Pētniecība un Attīstība | 148.725 | 161.107 | 157.869 | 161.092 | 160.836 |
| Depreciation / Amortization | 15.4 | 15.5 | 15.4 | 15.6 | 15.6 |
| Neparedzēti Izdevumi (Ienākumi) | 0 | 0 | 0 | 0 | -108 |
| Other Operating Expenses, Total | 2.335 | 2.191 | 1.822 | 1.685 | 2.012 |
| Darbības Izdevumi | 25.086 | 11.672 | -53.219 | -65.88 | 137.327 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -2.716 | 0.479 | -1.866 | -0.752 | -1.986 |
| Citi, Neto | 0.858 | 2.005 | 8.925 | 0.058 | -1.154 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 23.228 | 14.156 | -46.16 | -66.574 | 134.187 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
| Neto Ienākumi | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
| Atšķaidītie Neto Ienākumi | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
| Atšķaidītie Ienākumi par Akcijām | 184.365 | 185.427 | 183.214 | 183.56 | 194.886 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 0.09422 | 0.06979 | -0.19919 | -0.33677 | 0.61984 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | 0.09422 | 0.06979 | -0.19919 | -0.33677 | 0.12096 |
| Ārkārtas Posteņi Kopā | 3.92 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 1421.79 | 2207.14 | 2056.22 | 1942.14 | 2342.22 | 2274.39 |
| Nauda un Īstermiņa Ieguldījumi | 789.677 | 1395.97 | 1084.31 | 753.807 | 1065.39 | 1013.88 |
| Nauda un Ekvivalenti | 408.33 | 598.028 | 493.982 | 437.446 | 649.158 | 587.276 |
| Īstermiņa Ieguldījumi | 381.347 | 797.94 | 590.326 | 316.361 | 416.228 | 426.599 |
| Debitoru Parādu Kopsumma, Neto | 215.28 | 261.365 | 342.633 | 377.404 | 448.351 | 373.399 |
| Accounts Receivable - Trade, Net | 215.28 | 261.365 | 342.633 | 377.404 | 448.351 | 373.399 |
| Total Inventory | 355.126 | 475.775 | 530.871 | 680.275 | 698.548 | 776.669 |
| Other Current Assets, Total | 61.708 | 74.036 | 98.403 | 130.657 | 129.934 | 110.442 |
| Total Assets | 4023.69 | 4633.12 | 4427.13 | 4690.04 | 5848.02 | 6003.33 |
| Property/Plant/Equipment, Total - Net | 798.768 | 896.7 | 948.682 | 1070.3 | 1089.58 | 1081.88 |
| Property/Plant/Equipment, Total - Gross | 1141.36 | 1303.43 | 1421.32 | 1619.4 | 1725.18 | 1802.45 |
| Accumulated Depreciation, Total | -342.594 | -406.734 | -472.635 | -549.1 | -635.595 | -720.574 |
| Goodwill, Net | 197.039 | 197.039 | 197.039 | 197.039 | 196.199 | 196.199 |
| Intangibles, Net | 553.78 | 517.51 | 491.808 | 456.58 | 417.271 | 388.652 |
| Long Term Investments | 572.711 | 385.785 | 235.864 | 411.978 | 285.473 | 507.793 |
| Other Long Term Assets, Total | 479.601 | 428.947 | 497.52 | 611.997 | 1517.28 | 1554.42 |
| Total Current Liabilities | 439.31 | 816.518 | 523.241 | 932.503 | 492.548 | 539.822 |
| Payable/Accrued | 198.53 | 161.652 | 208.119 | 240.981 | 191.429 | 193.003 |
| Accrued Expenses | 158.926 | 201.601 | 213.03 | 287.878 | 266.254 | 277.059 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 22.478 | 360.949 | 0 | 365.131 | 2.865 | 2.266 |
| Other Current Liabilities, Total | 59.376 | 92.316 | 102.092 | 38.513 | 32 | 67.494 |
| Total Liabilities | 1257.42 | 1824.46 | 1459.19 | 1567.66 | 1742.02 | 1732.58 |
| Total Long Term Debt | 660.761 | 813.521 | 830.417 | 492.946 | 1079.15 | 1081.04 |
| Long Term Debt | 660.761 | 813.521 | 830.417 | 486.238 | 1075.15 | 1079.08 |
| Deferred Income Tax | 0 | |||||
| Other Liabilities, Total | 157.344 | 194.423 | 105.53 | 142.209 | 170.319 | 111.726 |
| Total Equity | 2766.27 | 2808.66 | 2967.94 | 3122.38 | 4106 | 4270.74 |
| Common Stock | 0.173 | 0.176 | 0.178 | 0.18 | 0.182 | 0.184 |
| Additional Paid-In Capital | 4288.11 | 4483.22 | 4669.93 | 4832.71 | 4993.41 | 5191.5 |
| Retained Earnings (Accumulated Deficit) | -1520.51 | -1637.55 | -1694.13 | -1720.71 | -861.609 | -925.689 |
| Other Equity, Total | -1.505 | -34.463 | -6.113 | 6.638 | -29.867 | 6.116 |
| Total Liabilities & Shareholders’ Equity | 4023.69 | 4633.12 | 4427.13 | 4690.04 | 5848.02 | 6003.33 |
| Total Common Shares Outstanding | 172.648 | 175.844 | 178.253 | 179.838 | 181.741 | 183.913 |
| Unrealized Gain (Loss) | -2.722 | -1.917 | 3.565 | 3.889 | -1.373 | |
| Capital Lease Obligations | 6.708 | 4.006 | 1.96 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 2288.77 | 2357.84 | 2311.57 | 2274.39 | 2394.02 |
| Nauda un Īstermiņa Ieguldījumi | 1087.49 | 1123.4 | 1079.48 | 1013.88 | 1056.24 |
| Nauda un Ekvivalenti | 667.313 | 641.533 | 617.143 | 587.276 | 605.44 |
| Īstermiņa Ieguldījumi | 420.178 | 481.864 | 462.333 | 426.599 | 450.798 |
| Debitoru Parādu Kopsumma, Neto | 396.097 | 424.419 | 374.937 | 373.399 | 430.147 |
| Accounts Receivable - Trade, Net | 396.097 | 424.419 | 374.937 | 373.399 | 430.147 |
| Total Inventory | 713.929 | 710.975 | 749.406 | 776.669 | 786.356 |
| Other Current Assets, Total | 91.249 | 99.046 | 107.751 | 110.442 | 121.283 |
| Total Assets | 5805.05 | 5898.5 | 5977.48 | 6003.33 | 6062.71 |
| Property/Plant/Equipment, Total - Net | 1022.47 | 1026.58 | 1024.79 | 1035.46 | 1039.54 |
| Property/Plant/Equipment, Total - Gross | 1679.77 | 1704.7 | 1724.7 | 1756.04 | 1780.71 |
| Accumulated Depreciation, Total | -657.296 | -678.126 | -699.915 | -720.574 | -741.167 |
| Goodwill, Net | 196.199 | 196.199 | 196.199 | 196.199 | 196.199 |
| Intangibles, Net | 405.903 | 394.298 | 388.487 | 388.652 | 374.251 |
| Long Term Investments | 321.127 | 350.237 | 466.618 | 507.793 | 462.827 |
| Other Long Term Assets, Total | 1570.58 | 1573.35 | 1589.81 | 1600.83 | 1595.86 |
| Total Current Liabilities | 430.035 | 443.344 | 514.898 | 539.822 | 490.418 |
| Payable/Accrued | 165.001 | 176.073 | 203.321 | 203.467 | 187.81 |
| Accrued Expenses | 209.203 | 207.005 | 241.535 | 268.861 | 214.435 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 55.831 | 60.266 | 70.042 | 67.494 | 88.173 |
| Total Liabilities | 1643.04 | 1656.93 | 1711.33 | 1732.58 | 1671.39 |
| Total Long Term Debt | 1076.13 | 1077.11 | 1078.09 | 1079.08 | 1080.06 |
| Long Term Debt | 1076.13 | 1077.11 | 1078.09 | 1079.08 | 1080.06 |
| Other Liabilities, Total | 136.881 | 136.471 | 118.335 | 113.686 | 100.913 |
| Total Equity | 4162.01 | 4241.57 | 4266.15 | 4270.74 | 4391.31 |
| Common Stock | 0.183 | 0.183 | 0.184 | 0.184 | 0.185 |
| Additional Paid-In Capital | 5010.62 | 5083.83 | 5133.74 | 5191.5 | 5206.29 |
| Retained Earnings (Accumulated Deficit) | -844.238 | -831.297 | -867.791 | -925.689 | -804.891 |
| Unrealized Gain (Loss) | 2.387 | 1.821 | 1.218 | -1.373 | -9.264 |
| Other Equity, Total | -6.941 | -12.967 | -1.204 | 6.116 | -1.002 |
| Total Liabilities & Shareholders’ Equity | 5805.05 | 5898.5 | 5977.48 | 6003.33 | 6062.71 |
| Total Common Shares Outstanding | 182.671 | 183.322 | 183.567 | 183.913 | 184.902 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
| Nauda no Darbības | -227.837 | -8.757 | 20.208 | 48.262 | 85.365 | 304.536 |
| Nauda no Darbības | 96.912 | 87.861 | 95.671 | 105.3 | 105.172 | 108.039 |
| Deferred Taxes | -228.054 | 44.464 | -68.378 | -82.76 | -888.907 | -15.608 |
| Bezskaidras Naudas Preces | 693.791 | 69.923 | 119.546 | 150.662 | 234.417 | 210.151 |
| Cash Taxes Paid | 95.857 | 23.895 | 16.676 | 9.726 | 8.977 | 18.153 |
| Samaksātie Procenti Naudā | 8.643 | 8.544 | 11.623 | 8.552 | 12.178 | 10.395 |
| Izmaiņas Apgrozāmajā Kapitālā | -160.276 | -93.963 | -49.42 | -101.092 | -224.417 | 66.034 |
| Nauda no Ieguldījumu Darbībām | -484.047 | -305.459 | 264.351 | -31.026 | -53.621 | -366.313 |
| Kapitālie Izdevumi | -148.38 | -199.219 | -144.62 | -163.406 | -137.519 | -119.225 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -335.667 | -106.24 | 408.971 | 132.38 | 83.898 | -247.088 |
| Nauda no Darbībām ar Finansēšanu | 727.108 | 507.145 | -388.007 | -74.674 | 181.118 | -0.048 |
| Naudas Plūsma Finansēšanas Posteņos | -60.057 | -35.427 | -80.542 | -101.198 | -44.638 | -46.203 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 787.165 | 60.859 | 67.488 | 31.611 | 21.913 | 49.194 |
| Ārvalstu Valūtas Ietekme | -3.934 | -3.231 | -0.598 | 0.902 | -1.15 | -0.057 |
| Neto Izmaiņas Naudā | 11.29 | 189.698 | -104.046 | -56.536 | 211.712 | -61.882 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 481.713 | -374.953 | -5.087 | 203.843 | -3.039 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 17.371 | 30.312 | -6.182 | -64.08 | 120.798 |
| Cash From Operating Activities | 113.512 | 196.296 | 293.356 | 304.536 | -45.431 |
| Cash From Operating Activities | 27.983 | 55.214 | 82.053 | 108.039 | 27.343 |
| Deferred Taxes | 3.335 | 1.204 | -12.02 | -15.608 | 4.8 |
| Non-Cash Items | 56.553 | 111.414 | 163.355 | 210.151 | -61.68 |
| Cash Taxes Paid | 2.998 | 10.159 | 15.531 | 18.153 | 1.316 |
| Cash Interest Paid | 1.465 | 5.195 | 6.673 | 10.395 | 1.422 |
| Changes in Working Capital | 8.27 | -1.848 | 66.15 | 66.034 | -136.692 |
| Cash From Investing Activities | -70.788 | -191.045 | -310.892 | -366.313 | 87.782 |
| Capital Expenditures | -28.254 | -54.506 | -74.866 | -119.225 | -30.675 |
| Other Investing Cash Flow Items, Total | -42.534 | -136.539 | -236.026 | -247.088 | 118.457 |
| Cash From Financing Activities | -24.364 | -13.413 | -14.444 | -0.048 | -25.28 |
| Financing Cash Flow Items | -29.097 | -39.112 | -44.829 | -46.203 | -32.949 |
| Issuance (Retirement) of Stock, Net | 5.817 | 27.64 | 32.877 | 49.194 | 8.235 |
| Issuance (Retirement) of Debt, Net | -1.084 | -1.941 | -2.492 | -3.039 | -0.566 |
| Foreign Exchange Effects | -0.205 | 0.537 | -0.035 | -0.057 | 1.093 |
| Net Change in Cash | 18.155 | -7.625 | -32.015 | -61.882 | 18.164 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| PRIMECAP Management Company | Investment Advisor | 9.4838 | 17625505 | -52980 | 2022-09-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.1613 | 17026106 | 263453 | 2022-09-30 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 7.9494 | 14773963 | -233100 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.3137 | 9875458 | 113895 | 2022-09-30 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 4.1004 | 7620494 | 0 | 2022-09-30 | LOW |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 3.0607 | 5688259 | 129970 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.8402 | 5278438 | -117928 | 2022-09-30 | LOW |
| Viking Global Investors LP | Investment Advisor/Hedge Fund | 2.7437 | 5099164 | 46571 | 2022-09-30 | MED |
| Capital Research Global Investors | Investment Advisor | 2.6563 | 4936740 | 1394 | 2022-09-30 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 2.2221 | 4129724 | -71509 | 2022-09-30 | LOW |
| Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 1.9131 | 3555555 | 271555 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.353 | 2514523 | 42707 | 2022-09-30 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.2642 | 2349540 | 223693 | 2021-12-31 | LOW |
| Parnassus Investments, LLC | Investment Advisor | 1.2583 | 2338529 | -227551 | 2022-12-31 | LOW |
| Barclays Bank PLC | Investment Advisor | 1.1309 | 2101767 | 182659 | 2022-09-30 | MED |
| Palo Alto Investors LP | Hedge Fund | 1.0634 | 1976265 | -85108 | 2022-09-30 | LOW |
| Millennium Management LLC | Hedge Fund | 1.0085 | 1874272 | 348269 | 2022-09-30 | HIGH |
| Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.9306 | 1729432 | 1607478 | 2022-09-30 | HIGH |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 0.924 | 1717310 | 17600 | 2022-09-30 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.7732 | 1437057 | -102057 | 2022-09-30 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group +485000+
Tirgotāji
65000+
Ikmēneša aktīvie klienti
$48000000+
Ikmēneša ieguldījumu apjoms
$28000000+
Izmēģināt tagad Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Tirdzniecības komisija
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finanšu svira
20:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
BioMarin Company profile
Par BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc ir biotehnoloģiju uzņēmums. Uzņēmums izstrādā un komercializē terapiju cilvēkiem ar nopietnām un dzīvībai bīstamām retām slimībām un veselības stāvokļiem. Uzņēmuma portfelis sastāv no komerciāliem produktiem un vairākiem klīniskiem un pirmsklīniskajiem kandidātproduktiem dažādu slimību ārstēšanai. Uzņēmuma komerciālie produkti ir Aldurazyme (laronidāze), Brineura (cerliponāze alfa), Kuvan (sapropterīna dihidrohlorīds), Naglazyme (galsulfāze), Palynziq (pegvaliāze-pqpz), Vimizim (elosulfāze alfa) un Voxzogo (vosoritīds). Uzņēmuma izstrādes plānā ietilpst valoctocogene Roxaparvovec smagas pakāpes hemofilijas A ārstēšanai, Vosoritide ahondroplāzijas ārstēšanai, BMN 307 fenilketonūrijas (PKU) ārstēšanai un BMN 331 iedzimtas angioedēmas (HAE) ārstēšanai.
| Industry: | Biopharmaceuticals |
105 Digital Dr
NOVATO
CALIFORNIA 94949
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 485 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com